Olanib 150 (Olaparib)

Olanib 150 mg (Olaparib)

Olanib 150 mg (Olaparib) is a cutting-edge oral oncology medication used in the targeted treatment of several types of cancer, including ovarian, breast, pancreatic, and prostate cancer. It is a PARP inhibitor designed to exploit genetic weaknesses in cancer cells to stop them from growing.

This medication is manufactured by Everest Pharmaceuticals Ltd., a leading pharmaceutical company in Bangladesh, and is supplied globally by Mediaid Pharmacy. We are committed to providing patients and healthcare professionals worldwide with access to genuine, high-quality cancer treatments. This product is available for Export Only.

What is Olanib 150 mg (Olaparib)?

Olanib contains the active ingredient Olaparib, which belongs to a class of drugs known as poly (ADP-ribose) polymerase (PARP) inhibitors.

PARP is an enzyme in our cells that helps repair damaged DNA. Cancer cells with specific genetic mutations (like BRCA1 or BRCA2) already have trouble repairing their DNA. Olaparib works by blocking the PARP enzyme, which prevents the cancer cells from repairing themselves entirely. This leads to the death of the cancer cells while sparing healthy cells that still have functioning DNA repair mechanisms.

Indications for Use

Olanib 150 mg is indicated for the treatment of adult patients with specific genetic mutations in the following conditions:

• Ovarian Cancer: Used for maintenance treatment in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who are in response to chemotherapy, or for advanced ovarian cancer with a BRCA mutation.
• Breast Cancer: For patients with deleterious germline BRCA-mutated, HER2-negative metastatic breast cancer who have been treated with chemotherapy.
• Prostate Cancer: For metastatic castration-resistant prostate cancer with homologous recombination repair (HRR) gene mutations.
• Pancreatic Cancer: For maintenance treatment of metastatic pancreatic adenocarcinoma with a germline BRCA mutation.

Dosage & Administration

Olanib comes in tablet form. The standard recommended dosage for most indications is 300 mg taken orally twice daily.

• Daily Regimen: This typically means taking two 150 mg tablets in the morning and two 150 mg tablets in the evening (Total: 4 tablets per day).
• Pack Size: The box contains 120 tablets, which generally provides a full 30-day supply at the standard dosage.
• Administration: Tablets can be taken with or without food. Swallow the tablet whole; do not chew, crush, dissolve, or divide.

Always follow the specific dosage instructions provided by your qualified oncologist.

Manufacturer – Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a renowned manufacturer in the pharmaceutical industry, known for its high-tech production of specialized oncology drugs. With facilities that comply with international Good Manufacturing Practices (GMP), Everest ensures that Olanib is produced to the highest standards of safety, purity, and potency.

Supplier – Mediaid Pharmacy

Mediaid Pharmacy is your trusted global supplier and distributor of specialized oncology medicines, including Olanib 150 mg. We are dedicated to bridging the gap in global healthcare by ensuring patients have access to essential medications.

Mediaid Pharmacy is known for:

• Worldwide Shipping: We securely ship "Export Only" medications to patients, pharmacies, and hospitals across the globe.
• Guaranteed Authenticity: We source Olanib directly from Everest Pharmaceuticals to ensure you receive 100% genuine products.
• Patient-Centric Service: Our professional team provides dedicated support and ensures a seamless, confidential ordering process.
• Competitive Pricing: We strive to offer affordable solutions for advanced cancer care.

Why Choose Olanib 150 mg from Mediaid Pharmacy?

• Broad Efficacy: Approved for use in multiple cancer types with BRCA/HRR mutations.
• Convenient Formulation: The 150 mg tablet reduces the pill burden compared to older capsule formulations (which required taking more pills).
• Full Month Supply: The 120-tablet pack covers a complete month of treatment at the standard dose.
• Global Availability: Distributed efficiently by Mediaid Pharmacy with reliable shipping options.

Frequently Asked Questions (FAQs)

Q: Why does the box contain 120 tablets?
A: The standard dose is 4 tablets per day (2 in the morning, 2 at night). A pack of 120 tablets provides exactly 30 days of treatment.

Q: Do I have to take Olanib with food?
A: No, Olanib tablets can be taken with or without food.

Q: Is Olanib the same as chemotherapy?
A: Olanib is a targeted therapy (a PARP inhibitor), not traditional chemotherapy. It works by targeting specific genetic weaknesses in cancer cells.

Conclusion

Olanib 150 mg (Olaparib) is a vital therapeutic option for patients with BRCA-mutated cancers, offering a targeted approach that can significantly delay disease progression. Manufactured by Everest Pharmaceuticals and supplied by Mediaid Pharmacy, it provides a high-quality and accessible treatment option for patients worldwide.

Contact Us to Order or Inquire

For the latest pricing, bulk orders, or to speak with our pharmacy team about Olanib 150 mg (Olaparib), please contact us. We are available 24/7 to support your healthcare needs.

WhatsApp/WeChat: +8801773428128